FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Lipid status association with 25-hydroxy vitamin D: cross sectional study of end stage renal disease patients

Povezanost lipidnog statusa sa 25-hidroksi vitaminom D: studija preseka kod bolesnika sa krajnjim stadijumom bolesti bubrega

Thumbnail
2020
LIPID_STATUS_ASSOCIATION_pub_2020.pdf (179.1Kb)
Authors
Milinković, Neda
Sarić, Marija
Jovičić, Snežana
Mirković, Duško
Ležaić, Višnja
Ignjatović, Svetlana
Article (Published version)
Metadata
Show full item record
Abstract
Background:Some observational studies indicate an association of 25-hydroxy vitamin D (25(OH)D) insufficiency and atherogenic cholesterol concentrations. The aim of this study was to investigate relationship between 25(OH)D concentrations and lipid parameters in end stage renal disease (ESRD) patients, separately for predialysis, hemodialysis and peritoneal dialysis patients.Methods:We have adjusted 25(OH)D concentrations for seasonal variability with cosinor analysis, and performed all further analysis using these corrected 25(OH)D concentrations. Concentrations of 25(OH)D and the lipid parameters were determined in 214 ESRD patients and 50 control group participants. The analysis included the measurement of 25(OH)D by HPLC, apolipoprotein (Apo) AI, ApoB andLp(a) by nephelometry, total cholesterol (TC), high-densitylipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) by spectrophotometry an...d manually calculated ApoB/ApoAI and LDL-C/HDL-C ratio.Results:ESRD patients with adjusted 25(OH)D concentrations of ≤ 50 nmol/L had significantly higher TC (P =0.005) and ApoAI (P = 0.049). Significantly higher HDL-C (P = 0.011) and ApoAI (P = 0.020) were found in hemodialysis patients with the 25(OH)D concentrations of ≤ 50 nmol/L. The other analyzed lipid parameters differed significantly between predialysis, hemodialysis and peritoneal dialysis patients with 25(OH)D concentrations of <50 nmol/L. Conclusions:Our study indicate the significant relationship between 25(OH)D repletion and optimal concentrations of lipid parameters in ESRD patients. Further research is necessary to explain whether joint evaluation of vitamin D status and lipid abnormalities could improve cardiovascular outcome in ESRD patients.

Uvod: Opservacione studije ukazuju na povezanost nedostatka 25-hidroksi vitamin D (25(OH)D) i koncentracija aterogenog holesterola. Cilj ove studije bio je da se ispita međusobna povezanost 25(OH)D i lipidnih parametara kod bolesnika sa krajnjim stadijumom bolesti bubrega (ESRD) posebno kod predijaliznih, bolesnika na hemodijalizi i peritonalnoj dijalizi. Metode: Podesili smo koncentracije 25(OH)D za sezonsku varijaciju koristeći kosinor analizu, i u daljem ispitivanju smo koristili korigovane koncentracije 25(OH)D. Koncentracije 25(OH)D i lipidnih parametara su određene za 214 ESRD bolesnika i 50 učesnika kontrolne grupe. Analizirali smo koncentracije 25(OH)D metodom HPLC, apolipoproteina (Apo) AI, ApoB i Lp(a) nefelometrijski, ukupnog holesterola (TC), lipoproteina velike gustine (HDL-C), lipoproteina male gustine (LDL-C) i triglicerida (TG) spektro fotometrijski i ručno preračunavali indekse ApoB/ApoAI i LDL-C/HDLC. Rezultati: ESRD bolesnici sa korigovanim 25(OH)D 50 nmol/L su imali... značajno viši TC (P = 0,005) i ApoAI (P = 0,049). Značajno više koncentracije HDL-C (P = 0,011) i ApoAI (P = 0,020) smo dobili kod hemodijaliznih bolesnika sa 25(OH)D koncentracijama 50 nmol/L. Ostali analizirani lipidni parametri su bili značajno različiti između analiziranih grupa bolesnika sa 25(OH)D koncentracijama < 50 nmol/L. Zaključak: Naša studija ukazuje na značajnu povezanost dovoljnih nivoa 25(OH)D i optimalnih koncentracija lipidnih parametara kod ESRD bolesnika. Potrebna su dalja istraživanja da bi se objasnilo da li zajednička procena statusa vitamina D i lipidnih abnormalnosti mogu da poboljšaju kardiovaskularni ishod kod ESRD bolesnika.

Keywords:
lipid parameters / 25-hydroxy vitamin D / end stage renal disease / dialysis / lipidni parametri / 25-hidroksi vitamin D / krajnji stadijum bolesti bubrega / dijaliza
Source:
Journal of Medical Biochemistry, 2020, 39, 3, 309-317
Publisher:
  • Beograd : Društvo medicinskih biohemičara Srbije
Funding / projects:
  • Interactive role of dyslipidemia, oxidative stress and inflammation in atherosclerosis and other diseases: genetic and biochemical markers (RS-175035)

DOI: 10.2478/jomb-2019-0032

ISSN: 1452-8258

WoS: 000543795100006

[ Google Scholar ]
2
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/3624
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Milinković, Neda
AU  - Sarić, Marija
AU  - Jovičić, Snežana
AU  - Mirković, Duško
AU  - Ležaić, Višnja
AU  - Ignjatović, Svetlana
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3624
AB  - Background:Some observational studies indicate an association  of  25-hydroxy  vitamin  D  (25(OH)D)  insufficiency and  atherogenic  cholesterol  concentrations.  The  aim  of this study was to investigate relationship between 25(OH)D concentrations  and  lipid  parameters  in  end  stage  renal disease  (ESRD)  patients,  separately  for  predialysis,  hemodialysis and peritoneal dialysis patients.Methods:We  have  adjusted  25(OH)D  concentrations  for seasonal variability with cosinor analysis, and performed all further analysis using these corrected 25(OH)D concentrations. Concentrations of 25(OH)D and the lipid parameters were  determined  in  214  ESRD  patients  and  50  control group participants. The analysis included the measurement of 25(OH)D by HPLC, apolipoprotein (Apo) AI, ApoB andLp(a) by nephelometry, total cholesterol (TC), high-densitylipoprotein  cholesterol  (HDL-C),  low-density  lipoprotein cholesterol  (LDL-C)  and  triglyceride  (TG)  by  spectrophotometry   and   manually   calculated   ApoB/ApoAI   and LDL-C/HDL-C ratio.Results:ESRD patients with adjusted 25(OH)D concentrations  of  ≤ 50  nmol/L  had  significantly  higher  TC  (P  =0.005) and ApoAI (P = 0.049). Significantly higher HDL-C  (P  =  0.011)  and  ApoAI  (P  =  0.020)  were  found  in hemodialysis patients with the 25(OH)D concentrations of ≤ 50 nmol/L. The other analyzed lipid parameters differed significantly  between  predialysis,  hemodialysis  and  peritoneal dialysis patients with 25(OH)D concentrations of <50 nmol/L. Conclusions:Our study indicate the significant relationship between 25(OH)D repletion and optimal concentrations of lipid parameters in ESRD patients. Further research is necessary  to  explain  whether  joint  evaluation  of  vitamin  D status and lipid abnormalities could improve cardiovascular outcome in ESRD patients.
AB  - Uvod: Opservacione studije ukazuju na povezanost nedostatka 25-hidroksi vitamin D (25(OH)D) i koncentracija aterogenog holesterola. Cilj ove studije bio je da se ispita međusobna povezanost 25(OH)D i lipidnih parametara kod bolesnika sa krajnjim stadijumom bolesti bubrega (ESRD) posebno kod predijaliznih, bolesnika na hemodijalizi i peritonalnoj dijalizi. Metode: Podesili smo koncentracije 25(OH)D za sezonsku varijaciju koristeći kosinor analizu, i u daljem ispitivanju smo koristili korigovane koncentracije 25(OH)D. Koncentracije 25(OH)D i lipidnih parametara su određene za 214 ESRD bolesnika i 50 učesnika kontrolne grupe. Analizirali smo koncentracije 25(OH)D metodom HPLC, apolipoproteina (Apo) AI, ApoB i Lp(a) nefelometrijski, ukupnog holesterola (TC), lipoproteina velike gustine (HDL-C), lipoproteina male gustine (LDL-C) i triglicerida (TG) spektro fotometrijski i ručno preračunavali indekse ApoB/ApoAI i LDL-C/HDLC. Rezultati: ESRD bolesnici sa korigovanim 25(OH)D 50 nmol/L su imali značajno viši TC (P = 0,005) i ApoAI (P = 0,049). Značajno više koncentracije HDL-C (P = 0,011) i ApoAI (P = 0,020) smo dobili kod hemodijaliznih bolesnika sa 25(OH)D koncentracijama 50 nmol/L. Ostali analizirani lipidni parametri su bili značajno različiti između analiziranih grupa bolesnika sa 25(OH)D koncentracijama < 50 nmol/L. Zaključak: Naša studija ukazuje na značajnu povezanost dovoljnih nivoa 25(OH)D i optimalnih koncentracija lipidnih parametara kod ESRD bolesnika. Potrebna su dalja istraživanja da bi se objasnilo da li zajednička procena statusa vitamina D i lipidnih abnormalnosti mogu da poboljšaju kardiovaskularni ishod kod ESRD bolesnika.
PB  - Beograd : Društvo medicinskih biohemičara Srbije
T2  - Journal of Medical Biochemistry
T1  - Lipid status association with 25-hydroxy vitamin D: cross sectional study of end stage renal disease patients
T1  - Povezanost lipidnog statusa sa 25-hidroksi vitaminom D: studija preseka kod bolesnika sa krajnjim stadijumom bolesti bubrega
VL  - 39
IS  - 3
SP  - 309
EP  - 317
DO  - 10.2478/jomb-2019-0032
ER  - 
@article{
author = "Milinković, Neda and Sarić, Marija and Jovičić, Snežana and Mirković, Duško and Ležaić, Višnja and Ignjatović, Svetlana",
year = "2020",
abstract = "Background:Some observational studies indicate an association  of  25-hydroxy  vitamin  D  (25(OH)D)  insufficiency and  atherogenic  cholesterol  concentrations.  The  aim  of this study was to investigate relationship between 25(OH)D concentrations  and  lipid  parameters  in  end  stage  renal disease  (ESRD)  patients,  separately  for  predialysis,  hemodialysis and peritoneal dialysis patients.Methods:We  have  adjusted  25(OH)D  concentrations  for seasonal variability with cosinor analysis, and performed all further analysis using these corrected 25(OH)D concentrations. Concentrations of 25(OH)D and the lipid parameters were  determined  in  214  ESRD  patients  and  50  control group participants. The analysis included the measurement of 25(OH)D by HPLC, apolipoprotein (Apo) AI, ApoB andLp(a) by nephelometry, total cholesterol (TC), high-densitylipoprotein  cholesterol  (HDL-C),  low-density  lipoprotein cholesterol  (LDL-C)  and  triglyceride  (TG)  by  spectrophotometry   and   manually   calculated   ApoB/ApoAI   and LDL-C/HDL-C ratio.Results:ESRD patients with adjusted 25(OH)D concentrations  of  ≤ 50  nmol/L  had  significantly  higher  TC  (P  =0.005) and ApoAI (P = 0.049). Significantly higher HDL-C  (P  =  0.011)  and  ApoAI  (P  =  0.020)  were  found  in hemodialysis patients with the 25(OH)D concentrations of ≤ 50 nmol/L. The other analyzed lipid parameters differed significantly  between  predialysis,  hemodialysis  and  peritoneal dialysis patients with 25(OH)D concentrations of <50 nmol/L. Conclusions:Our study indicate the significant relationship between 25(OH)D repletion and optimal concentrations of lipid parameters in ESRD patients. Further research is necessary  to  explain  whether  joint  evaluation  of  vitamin  D status and lipid abnormalities could improve cardiovascular outcome in ESRD patients., Uvod: Opservacione studije ukazuju na povezanost nedostatka 25-hidroksi vitamin D (25(OH)D) i koncentracija aterogenog holesterola. Cilj ove studije bio je da se ispita međusobna povezanost 25(OH)D i lipidnih parametara kod bolesnika sa krajnjim stadijumom bolesti bubrega (ESRD) posebno kod predijaliznih, bolesnika na hemodijalizi i peritonalnoj dijalizi. Metode: Podesili smo koncentracije 25(OH)D za sezonsku varijaciju koristeći kosinor analizu, i u daljem ispitivanju smo koristili korigovane koncentracije 25(OH)D. Koncentracije 25(OH)D i lipidnih parametara su određene za 214 ESRD bolesnika i 50 učesnika kontrolne grupe. Analizirali smo koncentracije 25(OH)D metodom HPLC, apolipoproteina (Apo) AI, ApoB i Lp(a) nefelometrijski, ukupnog holesterola (TC), lipoproteina velike gustine (HDL-C), lipoproteina male gustine (LDL-C) i triglicerida (TG) spektro fotometrijski i ručno preračunavali indekse ApoB/ApoAI i LDL-C/HDLC. Rezultati: ESRD bolesnici sa korigovanim 25(OH)D 50 nmol/L su imali značajno viši TC (P = 0,005) i ApoAI (P = 0,049). Značajno više koncentracije HDL-C (P = 0,011) i ApoAI (P = 0,020) smo dobili kod hemodijaliznih bolesnika sa 25(OH)D koncentracijama 50 nmol/L. Ostali analizirani lipidni parametri su bili značajno različiti između analiziranih grupa bolesnika sa 25(OH)D koncentracijama < 50 nmol/L. Zaključak: Naša studija ukazuje na značajnu povezanost dovoljnih nivoa 25(OH)D i optimalnih koncentracija lipidnih parametara kod ESRD bolesnika. Potrebna su dalja istraživanja da bi se objasnilo da li zajednička procena statusa vitamina D i lipidnih abnormalnosti mogu da poboljšaju kardiovaskularni ishod kod ESRD bolesnika.",
publisher = "Beograd : Društvo medicinskih biohemičara Srbije",
journal = "Journal of Medical Biochemistry",
title = "Lipid status association with 25-hydroxy vitamin D: cross sectional study of end stage renal disease patients, Povezanost lipidnog statusa sa 25-hidroksi vitaminom D: studija preseka kod bolesnika sa krajnjim stadijumom bolesti bubrega",
volume = "39",
number = "3",
pages = "309-317",
doi = "10.2478/jomb-2019-0032"
}
Milinković, N., Sarić, M., Jovičić, S., Mirković, D., Ležaić, V.,& Ignjatović, S.. (2020). Lipid status association with 25-hydroxy vitamin D: cross sectional study of end stage renal disease patients. in Journal of Medical Biochemistry
Beograd : Društvo medicinskih biohemičara Srbije., 39(3), 309-317.
https://doi.org/10.2478/jomb-2019-0032
Milinković N, Sarić M, Jovičić S, Mirković D, Ležaić V, Ignjatović S. Lipid status association with 25-hydroxy vitamin D: cross sectional study of end stage renal disease patients. in Journal of Medical Biochemistry. 2020;39(3):309-317.
doi:10.2478/jomb-2019-0032 .
Milinković, Neda, Sarić, Marija, Jovičić, Snežana, Mirković, Duško, Ležaić, Višnja, Ignjatović, Svetlana, "Lipid status association with 25-hydroxy vitamin D: cross sectional study of end stage renal disease patients" in Journal of Medical Biochemistry, 39, no. 3 (2020):309-317,
https://doi.org/10.2478/jomb-2019-0032 . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB